Search results for: Paul Matthias Diderichsen

Items from 1 to 6 out of 6 results

article

Population Pharmacokinetics of Mivavotinib (TAK‐659), a Dual Spleen Tyrosine Kinase and FMS‐Like Tyrosine Kinase 3 Inhibitor, in Patients With Advanced Solid Tumors or Hematologic Malignancies

Cheryl Li, Kenny Watson, Shining Wang, Paul Matthias Diderichsen, more

The Journal of Clinical Pharmacology > 63 > 3 > 326 - 337

Mivavotinib (TAK‐659), an orally administered, small‐molecule, dual inhibitor of spleen tyrosine kinase and FMS‐like tyrosine kinase 3 (SYK/FLT3), is under development for the treatment of patients with advanced malignancies. In this analysis, we evaluated the population pharmacokinetics (PK) of mivavotinib and its sources of variability (covariates) in adult patients with advanced solid tumors, or...

article

Population Pharmacokinetics of TAK‐931, a Cell Division Cycle 7 Kinase Inhibitor, in Patients With Advanced Solid Tumors

Xiaofei Zhou, Aziz Ouerdani, Paul Matthias Diderichsen, Neeraj Gupta

The Journal of Clinical Pharmacology > 62 > 3 > 422 - 433

A population pharmacokinetic (PK) analysis was conducted to characterize sources of interpatient variability on the PK of TAK‐931, a cell division cycle 7 kinase inhibitor, in adult patients with advanced solid tumors using data from 198 patients who received oral TAK‐931 over the range of 30 to 150 mg once daily in multiple dosing schedules in 2 phase 1 and 1 phase 2 clinical studies. A 2‐compartment...

article

Population Pharmacokinetic and Pharmacodynamic Analysis of GLPG1690, an Autotaxin Inhibitor, in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis

Amit Taneja, Julie Desrivot, Paul Matthias Diderichsen, Roland Blanqué, more

Clinical Pharmacokinetics > 2019 > 58 > 9 > 1175-1191

Background and Objectives GLPG1690 is an autotaxin inhibitor in development for the treatment of idiopathic pulmonary fibrosis. Several publications suggested a role of autotaxin in the control of disease-affected lung function and of lysophosphatidic acid in lung remodeling processes. The aim of the current article was to describe the exposure–response relationship of GLPG1690 and further develop...

article

Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection

Florence Namour, Paul Matthias Diderichsen, Eugène Cox, Béatrice Vayssière, more

Clinical Pharmacokinetics > 2015 > 54 > 8 > 859-874

Background and Objectives Filgotinib (GLPG0634) is a selective inhibitor of Janus kinase 1 (JAK1) currently in development for the treatment of rheumatoid arthritis and Crohn’s disease. While less selective JAK inhibitors have shown long-term efficacy in treating inflammatory conditions, this was accompanied by dose-limiting side effects. Here, we describe the pharmacokinetics of filgotinib and...

article

Predicted heart rate effect of inhaled PF‐00610355, a long acting β‐adrenoceptor agonist, in volunteers and patients with chronic obstructive pulmonary disease

Paul Matthias Diderichsen, Eugène Cox, Steven W. Martin, Adriaan Cleton, more

British Journal of Clinical Pharmacology > 76 > 5 > 752 - 762

AimTo assess the cardiovascular effects of a new inhaled long‐acting β‐adrenoceptor agonist PF‐00610355 in COPD patients. MethodsThirteen thousand and sixty‐two heart rate measurements collected in 10 clinical studies from 579 healthy volunteers, asthma and COPD patients were analyzed. The relationship between heart rate profiles and predicted plasma concentration profiles, patient status, demographics...

article

Characterizing Systemic Exposure of Inhaled Drugs: Application to the Long-Acting β₂-Agonist PF-00610355

Paul Matthias Diderichsen, Eugène Cox, Steven W. Martin, Adriaan Cleton, more

Clinical Pharmacokinetics > 2013 > 52 > 6 > 443-452

Background and Objectives PF-00610355 is an orally inhaled long-acting β₂-adrenoreceptor agonist that is being developed for the once-daily treatment of chronic obstructive pulmonary disease (COPD). The pharmacological effect is exerted in the lungs. However, systemic exposure of PF-00610355 is expected to be responsible for certain drug-related adverse effects. This analysis characterizes PF-00610355...

Filter options

Publication date

Last 3 years (2)

Close

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

From:

To:
Set your own date range

Keywords

Data set

Springer (3)
Wiley (3)

INFONA - science communication portal

Search results for: Paul Matthias Diderichsen

Population Pharmacokinetics of Mivavotinib (TAK‐659), a Dual Spleen Tyrosine Kinase and FMS‐Like Tyrosine Kinase 3 Inhibitor, in Patients With Advanced Solid Tumors or Hematologic Malignancies

Population Pharmacokinetics of TAK‐931, a Cell Division Cycle 7 Kinase Inhibitor, in Patients With Advanced Solid Tumors

Population Pharmacokinetic and Pharmacodynamic Analysis of GLPG1690, an Autotaxin Inhibitor, in Healthy Volunteers and Patients with Idiopathic Pulmonary Fibrosis

Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose Selection

Predicted heart rate effect of inhaled PF‐00610355, a long acting β‐adrenoceptor agonist, in volunteers and patients with chronic obstructive pulmonary disease

Characterizing Systemic Exposure of Inhaled Drugs: Application to the Long-Acting β2-Agonist PF-00610355

Add recipient

Sending message cancelled

Are you sure you want to cancel sending this message?

Send message

Filter options

Publication date

Date range setting

Set the date range to filter the displayed results. You can set a starting date, ending date or both. You can enter the dates manually or choose them from the calendar.

Keywords

Data set

Journal

Reporting an error / abuse

Sending the report failed

Accessibility options

Characterizing Systemic Exposure of Inhaled Drugs: Application to the Long-Acting β₂-Agonist PF-00610355